Endocyte Refocuses Development on Prostate Cancer Radioligand Therapeutic

Endocyte said today it has licensed ABX’s radioligand therapeutic (RLT) candidate PSMA-617 in a deal that could generate up to $172 million-plus for the German nuclear medicine company, adding that it will refocus the company’s development efforts around the prostate cancer treatment.During the first half of 2018, Endocyte plans to launch a Phase III trial for the RLT that it calls 177 Lu-PSMA-617, which targets the prostate-specific membrane antigen (PSMA), present in approximately